Geovanna Cárdenas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Geovanna Cárdenas has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Francisca Verdugo-Paiva
Center for Integrative Global Oral Health, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA
3 shared publications - Francisco Novillo
Faculty of Medicine, Pontificia Universidad Católica de Chile
3 shared publications - Gabriel Rada
Pontificia Universidad Católica de Chile
3 shared publications - Shuheng Lai
Faculty of Medicine, Pontificia Universidad Católica de Chile
3 shared publications - Héctor Fuenzalida-Wong
Universidad Católica de Chile
1 shared publication
Latest Publications
- Open Access
Hyaluronic acid for tissue and bone regeneration after tooth extraction. Systematic review and meta-analysis
Objective The objective of this systematic review is to assess the effectiveness and safety of Hyaluronic Acid (HA) on tissue and bone regeneration after tooth extraction. Data Sources We will conduct a comprehensive search in Epistemonikos, PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Eligibility Criteria for Selecting Studies and Methods We will include randomized trials evaluating the effect of HA on tissue and bone regeneration after tooth extraction. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be disseminated via peer-reviewed publications, social networks, and traditional media. PROSPERO Registration ID CRD42020150285
Open AccessHyaluronic acid for tissue and bone regeneration after tooth extraction. Systematic review and meta-analysis
Objective The objective of this systematic review is to assess the effectiveness and safety of Hyaluronic Acid (HA) on tissue and bone regeneration after tooth extraction. Data Sources We will conduct a comprehensive search in Epistemonikos, PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Eligibility Criteria for Selecting Studies and Methods We will include randomized trials evaluating the effect of HA on tissue and bone regeneration after tooth extraction. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be disseminated via peer-reviewed publications, social networks, and traditional media. PROSPERO Registration ID CRD42020150285
- Open Access
Periodontal therapy on disease activity of Rheumatoid Arthritis. Systematic review and meta-analysis
Objective The objective of this systematic review is to assess the impact of periodontal therapy on disease activity of patients with Rheumatoid Arthritis Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Elegibility Criteria for Selecting Studies and Methods We will include randomised trials evaluating the effect of periodontal therapy on disease activity of rheumatoid arthritis. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be disseminated via peer-reviewed publications, social networks and traditional media. PROSPERO Registration ID CRD42020150286.
Open AccessPeriodontal therapy on disease activity of Rheumatoid Arthritis. Systematic review and meta-analysis
Objective The objective of this systematic review is to assess the impact of periodontal therapy on disease activity of patients with Rheumatoid Arthritis Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Elegibility Criteria for Selecting Studies and Methods We will include randomised trials evaluating the effect of periodontal therapy on disease activity of rheumatoid arthritis. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be disseminated via peer-reviewed publications, social networks and traditional media. PROSPERO Registration ID CRD42020150286.
- Open Access
Oxymetazoline for the treatment of rosacea-associated persistent facial erythema. Systematic review and meta-analysis protocol
Objective The objective of this systematic review is to assess the impact of oxymetazoline in patients with moderate to severe rosacea. Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Eligibility criteria for selecting studies and methods We will include randomized trials evaluating the effect of oxymetazoline in patients with moderate to severe rosacea. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE [1] system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media. Protocol and Registration This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.
Open AccessOxymetazoline for the treatment of rosacea-associated persistent facial erythema. Systematic review and meta-analysis protocol
Objective The objective of this systematic review is to assess the impact of oxymetazoline in patients with moderate to severe rosacea. Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Eligibility criteria for selecting studies and methods We will include randomized trials evaluating the effect of oxymetazoline in patients with moderate to severe rosacea. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE [1] system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media. Protocol and Registration This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.